- •The ideal CD34 cell dose in sibling donor allogeneic stem cell transplantation is unclear.
- •This study shows higher CD34 cell dose is associated with better overall survival.
- •High CD34 cell dose also correlates with more chronic graft-versus-host disease.
- •Older female donors are at high risk for low CD34 collection yield.
- •A target CD34 cell dose of 7.5 × 106/kg is suggested for sibling donor transplants.
- Twenty-five years of peripheral blood stem cell transplantation.Blood. 2011; 117: 6411-6416
D'Souza A, Fretham C. Current use and outcomes of hematopoietic cell transplantation: CIBMTR US summary slides, 2019.
- CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation.Blood. 2001; 98: 3221-3227
- Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation.Blood. 2002; 99: 2726-2733
- Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses.Br J Haematol. 2003; 121: 874-885
- Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation.Leukemia. 2003; 17: 869-875
- Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation.Blood. 1999; 94: 1465-1470
- Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.Blood. 2003; 102: 1108-1113
- Low CD34 dose is associated with poor survival after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndrome.Biol Blood Marrow Transplant. 2014; 20: 1418-1425
- Higher doses of CD34+ progenitors are associated with improved overall survival without increasing GVHD in reduced-intensity conditioning allogeneic transplant recipients with clinically advanced disease.J Clin Apher. 2013; 28: 349-355
Yokoyama Y, Maie K, Fukuda T, et al. A high CD34+ cell dose is associated with better disease-free survival in patients with low-risk diseases undergoing peripheral blood stem cell transplantation from HLA-matched related donors. Bone Marrow Transplant. 2020;55:1726-1735.
- Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose.Blood. 2009; 114: 2606-2616
- Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation.Haematologica. 2016; 101: 499-505
- Effect of total nucleated and CD34(+) cell dose on outcome after allogeneic hematopoietic stem cell transplantation.Biol Blood Marrow Transplant. 2015; 21: 889-893
- Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond. The Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation.J Clin Oncol. 2006; 24: 3959-3966
- High CD3+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.Oncotarget. 2016; 7: 27255-27266
- The number of infused CD34+ cells does not influence the incidence of GVHD or the outcome of allogeneic PBSC transplantation, using reduced-intensity conditioning and antithymocyte globulin.Bone Marrow Transplant. 2010; 45: 1189-1196
- Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation.Blood. 2014; 123: 3664-3671
- Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the Center for International Blood and Marrow Transplant Research.Biol Blood Marrow Transplant. 2009; 15: 367-369
- 1994 Consensus Conference on Acute GVHD Grading.Bone Marrow Transplant. 1995; 15: 825-828
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.Biol Blood Marrow Transplant. 2015; 21 (e1): 389-401
- Efficacy of CD34+ stem cell dose in patients undergoing allogeneic peripheral blood stem cell transplantation after total body irradiation.Biol Blood Marrow Transplant. 2007; 13: 339-344
- Analysis of factors associated with successful allogeneic peripheral blood stem cell collection in healthy donors.Transfus Apher Sci. 2020; 59102679
- Factors associated with peripheral blood stem cell yield in volunteer donors mobilized with granulocyte colony-stimulating factors: the impact of donor characteristics and procedural settings.Biol Blood Marrow Transplant. 2008; 14: 1305-1311
- Donor experiences of second marrow or peripheral blood stem cell collection mirror the first, but CD34+ yields are less.Biol Blood Marrow Transplant. 2018; 24: 175-184
- Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft.Blood. 2017; 129: 2680-2692
- Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations.Biol Blood Marrow Transplant. 2014; 20: 295-308
- Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.Blood. 2009; 113: 5720-5726
Publication stageIn Press Uncorrected Proof
Financial disclosure: See Acknowledgments on page XXX.